BioTime's Subsidiary Enters Agreement Adding New Embryonic Stem Cell Lines to Its Product Portfolio (Centre Daily Times)
BioTime, Inc., (OTCBB:BTIM) announced today that its wholly-owned subsidiary Embryome Sciences, Inc. has entered into an agreement with Reproductive Genetics Institute (RGI) of Chicago, Illinois granting Embryome Sciences rights to market new human embryonic stem cell (hES) lines selected by Embryome Sciences from 294 hES lines derived by RGI. Embryome Sciences will initially select 10 RGI hES …
[Read the full article here]Related News:
Embryome Sciences to Enhance hESC Franchise by Gaining New Cell Lines – Genetic Engineering News
BioTime Adds Five New Stem Cell Lines to Its Product Portfolio
StemCells, Inc. to Acquire Cell-Based Drug Discovery Platforms and Related Businesses of Stem Cell Sciences plc (Centre Daily Times)